Virax Biolabs announces 1-for-10 share consolidation

Virax Biolabs Group announced that the annual general meetings of the shareholders held on Wednesday, December 6, 2023, at BioCity Glasgow, Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH, approved the proposed 1-for-10 share consolidation of its ordinary shares of $0.0001 par value each. Beginning with the opening of trading on December 18, 2023, the company’s ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol “VRAX“, but under a new CUSIP number of G9495L125. The objective of the Share Consolidation is to enable the company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market.